C. Muzica

发表

Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases: The Heart of the Matter

A. Sîngeap, C. Stanciu, A. Trifan, 2021, Canadian journal of gastroenterology & hepatology.

Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: A Bidirectional Relationship

A. Sîngeap, C. Stanciu, A. Trifan, 2020, Canadian journal of gastroenterology & hepatology.

Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end

A. Sîngeap, C. Stanciu, A. Trifan, 2020, World journal of gastroenterology.

L3 Skeletal Muscle Index Dynamics in Patients with HCV-Related Compensated Cirrhosis Following Sustained Virological Response after Direct Acting Antiviral Treatment

A. Sîngeap, C. Stanciu, A. Trifan, 2021, Medicina.

The Socio-Economic Burden of Untreated Hepatitis C Virus Infected Patients in the Era of New Interferon-Free Therapy

A. Sîngeap, C. Stanciu, A. Trifan, 2018 .

Efficacy and safety of alisporivir for the treatment of hepatitis C infection

C. Stanciu, A. Trifan, C. Sfarti, 2019, Expert opinion on pharmacotherapy.

Long-term Risk of Hepatocellular Carcinoma Following Direct-Acting Antiviral Therapy in Compensated Liver Cirrhosis Induced by Hepatitis C Virus Infection

A. Sîngeap, C. Stanciu, A. Trifan, 2021, Hepatitis Monthly.

Nonalcoholic Fatty Liver Disease-Related Chronic Kidney Disease

A. Sîngeap, C. Stanciu, A. Trifan, 2020, Canadian journal of gastroenterology & hepatology.

Association between Nonalcoholic Fatty Liver Disease and Endocrinopathies: Clinical Implications

A. Sîngeap, C. Stanciu, A. Trifan, 2021, Canadian journal of gastroenterology & hepatology.

The Risk of Clostridioides difficile Infection in Cirrhotic Patients Receiving Norfloxacin for Secondary Prophylaxis of Spontaneous Bacterial Peritonitis—A Real Life Cohort

A. Sîngeap, C. Stanciu, A. Trifan, 2021, Medicina.

Simultaneously Screening for Liver Steatosis and Fibrosis in Romanian Type 2 Diabetes Mellitus Patients Using Vibration-Controlled Transient Elastography with Controlled Attenuation Parameter

A. Sîngeap, C. Stanciu, A. Trifan, 2022, Diagnostics.

Vibration-Controlled Transient Elastography and Controlled Attenuation Parameter for the Diagnosis of Liver Steatosis and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease

A. Sîngeap, C. Stanciu, A. Trifan, 2021, Diagnostics.

SHORT-TERM CHANGES OF LIVER FIBROSIS IN PATIENTS WITH HCV GENOTYPE 1b - RELATED COMPENSATED CIRRHOSIS AFTER SUSTAINED VIROLOGIC RESPONSE SHORT-TERM ASSESSEMENT OF LIVER FIBROSIS REGRESSION IN PATIENTS WITH HCV GENOTYPE 1b - RELATED CIRRHOSIS AFTER SUSTAINED VIROLOGIC

A. Sîngeap, C. Stanciu, A. Trifan, 2021 .

An update on direct antiviral agents for the treatment of hepatitis C

A. Sîngeap, C. Stanciu, A. Trifan, 2021, Expert opinion on pharmacotherapy.

Ischemic Heart Disease and Liver Cirrhosis: Adding Insult to Injury

A. Sîngeap, C. Stanciu, A. Trifan, 2022, Life.

Clinical and Laboratory Characteristics of Normal Weight and Obese Individuals with Non-Alcoholic Fatty Liver Disease

A. Sîngeap, C. Stanciu, A. Trifan, 2022, Diagnostics.

Screening for Liver Steatosis and Fibrosis in Patients with Inflammatory Bowel Disease Using Vibration Controlled Transient Elastography with Controlled Attenuation Parameter

A. Sîngeap, C. Stanciu, A. Trifan, 2022, Journal of clinical medicine.

The Role of Presepsin and Procalcitonin in Early Diagnosis of Bacterial Infections in Cirrhotic Patients with Acute-on-Chronic Liver Failure

M. Blaj, A. Sîngeap, C. Stanciu, 2022, Journal of clinical medicine.

The Role of Presepsin in Diagnosing Infections in Patients with Liver Cirrhosis and Overt Hepatic Encephalopathy

M. Blaj, A. Sîngeap, C. Stanciu, 2022, Diagnostics.

Predictive Factors for the Prognosis of Alcoholic Liver Cirrhosis

A. Sîngeap, C. Stanciu, A. Trifan, 2022, Medicina.

Micro-elimination of hepatitis C virus infection - the beginning of the end.

C. Stanciu, A. Trifan, T. Cuciureanu, 2020, Journal of gastrointestinal and liver diseases : JGLD.

Did the severe acute respiratory syndrome-coronavirus 2 pandemic cause an endemic Clostridium difficile infection?

A. Sîngeap, C. Stanciu, A. Trifan, 2021, World journal of clinical cases.

Hepatitis C Virus Prevalence and Risk Factors in a Village in Northeastern Romania—A Population-Based Screening—The First Step to Viral Micro-Elimination

A. Sîngeap, C. Stanciu, A. Trifan, 2021, Healthcare.

Changes in Components of Metabolic Syndrome after Antiviral Eradication in Hepatitis C Virus Infection

A. Sîngeap, C. Stanciu, A. Trifan, 2023, Life.

Changes in Liver Steatosis Using Controlled Attenuation Parameter among Patients with Chronic Hepatitis C Infection Treated with Direct-Acting Antivirals Therapy Who Achieved Sustained Virological Response

A. Sîngeap, C. Stanciu, A. Trifan, 2022, Diagnostics.

Idiopathic Cervical Esophageal Webs: A Case Report and Literature Review

C. Stanciu, A. Trifan, I. Gîrleanu, 2020, International journal of general medicine.

Impaired Intestinal Permeability Assessed by Confocal Laser Endomicroscopy—A New Potential Therapeutic Target in Inflammatory Bowel Disease

A. Sîngeap, C. Stanciu, A. Trifan, 2023, Diagnostics.

Quality of life in patients with non-alcoholic fatty liver disease

A. Sîngeap, L. Huiban, C. Muzica, 2020 .

High prevalence of liver fibrosis among general population: a Romanian population-based study

A. Sîngeap, C. Stanciu, A. Trifan, 2023, Hepatology communications.

The Prevalence of Liver Steatosis and Fibrosis Assessed by Vibration-Controlled Transient Elastography and Controlled Attenuation Parameter in Apparently Healthy Romanian Medical Students

A. Sîngeap, C. Stanciu, A. Trifan, 2021, Diagnostics.

Accuracy of AST to platelet ratio for predicting liver fibrosis in patients with chronic HCV infection after viral eradication

C. Stanciu, A. Trifan, T. Cuciureanu, 2021, Revista Medico-Chirurgicala.

Coagulation Dysfunctions in Non-Alcoholic Fatty Liver Disease—Oxidative Stress and Inflammation Relevance

A. Ciobica, M. Robea, A. Trifan, 2023, Medicina.

Anticoagulation for Atrial Fibrillation in Patients with Decompensated Liver Cirrhosis: Bold and Brave?

A. Sîngeap, C. Stanciu, A. Trifan, 2023, Diagnostics.

Challenges and Solutions in the Management of Hepatocellular Carcinoma Associated with Non-Alcoholic Fatty Liver Disease

C. Muzica, A. Trofin, M. Zabara, 2023, Life.

380 EXCELLENT LONG-TERM NEGATIVE PREDICTIVE VALUE OF CAPSULE ENDOSCOPY IN SUSPECTED ISOLATED SMALL BOWEL CROHN’S DISEASE

A. Sîngeap, A. Trifan, T. Cuciureanu, 2022 .

Reclassification of Inflammatory Bowel Disease Type Unclassified by Small Bowel Capsule Endoscopy

A. Sîngeap, A. Trifan, I. Gîrleanu, 2023, Medicina.

A Comprehensive Overview of the Past, Current, and Future Randomized Controlled Trials in Hepatic Encephalopathy

O. Ilie, A. Trifan, P. Cianga, 2023, Medicina.

New Insights on Using Oral Semaglutide versus Dapagliflozin in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease

A. Sîngeap, A. Trifan, T. Cuciureanu, 2024, Diagnostics.